Cipla Launches Mobile App for Asthma Screening in India

Pharmaceutical company Cipla announced the rollout of a mobile app aimed at facilitating the initial screening for asthma in India. The Global Burden of Disease report estimates that asthma's total burden in India is roughly 34.3 million. India experiences a mortality rate three times higher and a disability burden related to asthma that is twice as high compared to the global average. This can be linked, in part, to the underdiagnosing and undertreating of asthma.

"By leveraging the power of next-gen technologies, we are developing solutions that are fundamentally transforming patient care and enabling better diagnostic, treatment, and management outcomes," Cipla Managing Director & Global CEO Umang Vohra said in a statement.

The company announced that the mobile app -- CipAir will first launch on Android and will later be introduced on iOS devices.

Cipla Limited is a multinational pharmaceutical firm based in Mumbai, India. Cipla mainly concentrates on creating drugs for respiratory illnesses, cardiovascular issues, arthritis, diabetes, depression, pediatric conditions, and several other health disorders. Cipla operates 47 production sites globally and markets its products in 86 nations. It ranks as the third-biggest drug producer in India.